Grifols, S.A. (GRFS)
After hours:
| Previous close | 6.30 |
| Open | 6.49 |
| Bid | 6.47 x 800 |
| Ask | 6.50 x 800 |
| Day's range | 6.43 - 6.66 |
| 52-week range | 5.30 - 12.15 |
| Volume | |
| Avg. volume | 2,148,400 |
| Market cap | 5.464B |
| Beta (5Y monthly) | 0.68 |
| PE ratio (TTM) | 64.80 |
| EPS (TTM) | 0.10 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 03 June 2021 |
| 1y target est | 15.81 |
PR NewswireGrifols 2023 Annual Report on Form 20-F filed with the SEC
Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the United States Securities and Exchange Commission ("SEC").
GlobeNewswireGrifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.
The addition of the Clayton site in 2011 marked a new milestone for Grifols, turning the company into a top-three plasma industry leader and setting the stage for sustained business growth The flagship Grifols campus is a touchstone of Grifols’ leadership in plasma therapeutics, producing about 40% of the company’s total medicinal output globally and helping enhance the quality of life of patients all over the worldAn engineering masterwork, the Clayton site is a model for new Grifols plants whi
ReutersSpanish drug maker Grifols will bring in independent directors, chairman tells newspaper
MADRID (Reuters) -Spanish drug maker Grifols, battling a plunge in its share price this year, plans to add independent directors to its audit and compensation committees to improve its governance, its chairman said in a newspaper interview published on Sunday. Grifols' market value has shed billions of euros since short-sheller Gotham City Research released three reports in early January accusing the company of overstating earnings and understating debt. Grifols has repeatedly denied the claims.
